63 related articles for article (PubMed ID: 30591449)
1. Bortezomib Is More Effective to Side Population of RPMI8226 Myeloma Cells than Classical Anti-myeloma Agents.
Kim KH; Cheong HJ; Lee MY; Lee N; Lee KT; Park SK; Won JH
Anticancer Res; 2019 Jan; 39(1):127-133. PubMed ID: 30591449
[TBL] [Abstract][Full Text] [Related]
2. Side population in human non-muscle invasive bladder cancer enriches for cancer stem cells that are maintained by MAPK signalling.
Hepburn AC; Veeratterapillay R; Williamson SC; El-Sherif A; Sahay N; Thomas HD; Mantilla A; Pickard RS; Robson CN; Heer R
PLoS One; 2012; 7(11):e50690. PubMed ID: 23226356
[TBL] [Abstract][Full Text] [Related]
3. Kinetic Modeling of ABCG2 Transporter Heterogeneity: A Quantitative, Single-Cell Analysis of the Side Population Assay.
Prasanphanich AF; White DE; Gran MA; Kemp ML
PLoS Comput Biol; 2016 Nov; 12(11):e1005188. PubMed ID: 27851764
[TBL] [Abstract][Full Text] [Related]
4. Connexin 43 gap junction affects survival and drug resistance of multiple myeloma side population cells.
Wang Z; Fu JX; Zhang XH; Sun Y; Ge XP
J Physiol Pharmacol; 2023 Jun; 74(3):. PubMed ID: 37661187
[TBL] [Abstract][Full Text] [Related]
5. Development of a cell adhesion-based prognostic model for multiple myeloma: Insights into chemotherapy response and potential reversal of adhesion effects.
Hu Q; Wang M; Wang J; Tao Y; Niu T
Oncol Res; 2024; 32(4):753-768. PubMed ID: 38560563
[TBL] [Abstract][Full Text] [Related]
6. Vitamin D and K Supplementation Is Associated with Changes in the Methylation Profile of U266-Multiple Myeloma Cells, Influencing the Proliferative Potential and Resistance to Bortezomib.
Łuczkowska K; Kulig P; Baumert B; Machaliński B
Nutrients; 2023 Dec; 16(1):. PubMed ID: 38201971
[TBL] [Abstract][Full Text] [Related]
7. Targeting gut microbial nitrogen recycling and cellular uptake of ammonium to improve bortezomib resistance in multiple myeloma.
Zhu Y; Jian X; Chen S; An G; Jiang D; Yang Q; Zhang J; Hu J; Qiu Y; Feng X; Guo J; Chen X; Li Z; Zhou R; Hu C; He N; Shi F; Huang S; Liu H; Li X; Xie L; Zhu Y; Zhao L; Jiang Y; Li J; Wang J; Qiu L; Chen X; Jia W; He Y; Zhou W
Cell Metab; 2024 Jan; 36(1):159-175.e8. PubMed ID: 38113887
[TBL] [Abstract][Full Text] [Related]
8. Retracted: Clinical Observation and Pharmacoeconomic Evaluations of Original Research Drug and Generic Drug Bortezomib in the Treatment of Multiple Myeloma.
Healthcare Engineering JO
J Healthc Eng; 2023; 2023():9806864. PubMed ID: 37799648
[TBL] [Abstract][Full Text] [Related]
9. Molecular signatures of multiple myeloma progression through single cell RNA-Seq.
Jang JS; Li Y; Mitra AK; Bi L; Abyzov A; van Wijnen AJ; Baughn LB; Van Ness B; Rajkumar V; Kumar S; Jen J
Blood Cancer J; 2019 Jan; 9(1):2. PubMed ID: 30607001
[TBL] [Abstract][Full Text] [Related]
10. Consolidation therapy with the combination of bortezomib and lenalidomide (VR) without dexamethasone in multiple myeloma patients after transplant: Effects on survival and bone outcomes in the absence of bisphosphonates.
Terpos E; Kastritis E; Ntanasis-Stathopoulos I; Christoulas D; Papatheodorou A; Eleutherakis-Papaiakovou E; Kanellias N; Fotiou D; Ziogas DC; Migkou M; Roussou M; Trougakos IP; Gavriatopoulou M; Dimopoulos MA
Am J Hematol; 2019 Apr; 94(4):400-407. PubMed ID: 30592079
[TBL] [Abstract][Full Text] [Related]
11. Effect of induction therapy with lenalidomide, doxorubicin and dexamethasone on bone remodeling and angiogenesis in newly diagnosed multiple myeloma.
Terpos E; Katodritou E; Symeonidis A; Zagouri F; Gerofotis A; Christopoulou G; Gavriatopoulou M; Christoulas D; Ntanasis-Stathopoulos I; Kourakli A; Konstantinidou P; Kastritis E; Dimopoulos MA
Int J Cancer; 2019 Jul; 145(2):559-568. PubMed ID: 30650184
[TBL] [Abstract][Full Text] [Related]
12. Targeting the cross-talk between the hedgehog and NF-κB signaling pathways in multiple myeloma.
Cai K; Na W; Guo M; Xu R; Wang X; Qin Y; Wu Y; Jiang J; Huang H
Leuk Lymphoma; 2019 Mar; 60(3):772-781. PubMed ID: 30644322
[TBL] [Abstract][Full Text] [Related]
13. The anti-myeloma effects of the selective JAK1 inhibitor (INCB052793) alone and in combination in vitro and in vivo.
Sanchez E; Li M; Patil S; Soof CM; Nosrati JD; Schlossberg RE; Vidisheva A; Tanenbaum EJ; Hekmati T; Zahab B; Wang C; Tang G; Chen H; Berenson JR
Ann Hematol; 2019 Mar; 98(3):691-703. PubMed ID: 30635766
[TBL] [Abstract][Full Text] [Related]
14. Targeting ubiquitin-activating enzyme induces ER stress-mediated apoptosis in B-cell lymphoma cells.
Best S; Hashiguchi T; Kittai A; Bruss N; Paiva C; Okada C; Liu T; Berger A; Danilov AV
Blood Adv; 2019 Jan; 3(1):51-62. PubMed ID: 30617217
[TBL] [Abstract][Full Text] [Related]
15. Prolonged survival with increasing duration of lenalidomide maintenance after autologous transplant for multiple myeloma.
Amsler IG; Jeker B; Mansouri Taleghani B; Bacher U; Betticher D; Egger T; Zander T; Luethi JM; Novak U; Pabst T
Leuk Lymphoma; 2019 Feb; 60(2):511-514. PubMed ID: 30616438
[No Abstract] [Full Text] [Related]
16. Lenalidomide for the treatment of mantle cell lymphoma.
Morabito F; Skafi M; Recchia AG; Kashkeesh A; Hindiyeh M; Sabatleen A; Morabito L; Alijanazreh H; Hamamreh Y; Gentile M
Expert Opin Pharmacother; 2019 Apr; 20(5):487-494. PubMed ID: 30608891
[TBL] [Abstract][Full Text] [Related]
17. High concentration of topical amitriptyline for treating chemotherapy-induced neuropathies.
Rossignol J; Cozzi B; Liebaert F; Hatton S; Viallard ML; Hermine O; Greco C
Support Care Cancer; 2019 Aug; 27(8):3053-3059. PubMed ID: 30607681
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation: a network meta-analysis.
Blommestein HM; van Beurden-Tan CHY; Franken MG; Uyl-de Groot CA; Sonneveld P; Zweegman S
Haematologica; 2019 May; 104(5):1026-1035. PubMed ID: 30606791
[TBL] [Abstract][Full Text] [Related]
19. Multiple myeloma with crystal-storing histiocytosis, crystalline podocytopathy, and light chain proximal tubulopathy, revealed by retinal abnormalities: A case report.
Boudhabhay I; Titah C; Talbot A; Harel S; Verine J; Touchard G; Kaaki S; Gabison E; Vasseur V; Mauget-Faÿsse M; Sené T
Medicine (Baltimore); 2018 Dec; 97(52):e13638. PubMed ID: 30593133
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib Maintenance for the Treatment of Monoclonal Gammopathy of Renal Significance.
Lee H; Duggan P; Neri P; Tay J; Jimenez-Zepeda VH
Mediterr J Hematol Infect Dis; 2019; 11(1):e2019007. PubMed ID: 30671213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
